ProCE Banner Activity

Phase III E1912: First-line Ibrutinib + Rituximab vs Standard-of-Care FCR in Younger Patients With Previously Untreated CLL

Slideset Download
Conference Coverage
This primary analysis demonstrated a statistically significant improvement in both PFS and OS with first-line ibrutinib plus rituximab vs FCR in patients younger than 70 years of age.

Released: December 07, 2018

Expiration: December 06, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology